Format

Send to

Choose Destination
BMC Cancer. 2017 Apr 27;17(1):292. doi: 10.1186/s12885-017-3192-x.

MiR-23b controls ALDH1A1 expression in cervical cancer stem cells.

Wang W1,2, Li Y1, Liu N3, Gao Y1, Li L4.

Author information

1
Department of Gynecology and Obstetrics, First Affiliated Hospital, Xi'an Jiaotong University, 277 West Yanta Road, 710061, Xi'an, China.
2
Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
3
Department of Ultrasound, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
4
Department of Gynecology and Obstetrics, First Affiliated Hospital, Xi'an Jiaotong University, 277 West Yanta Road, 710061, Xi'an, China. fuchanys@mail.xjtu.edu.cn.

Abstract

BACKGROUND:

Cancer stem cells has been widely investigated due to its essential role in cancer progression and drug resistance. Here, we try to find a new therapeutic target for cervical cancer stem cells.

METHODS:

We detected ALDH1A1-associated miRNAs expression in our isolated tumorspheres and their corresponding parental cells. Sphere formation assay was also used to determine stemness after cells were manipulated with miR-23b plasmid or miR-23b inhibitor.

RESULTS:

We found that miR-23b was under-expressed in cervical cancer stem cells to maintain high levels of ALDH1A1. Introduction of miR-23b into cervical cancer cells could alter stemness and cisplatin sensitivity.

CONCLUSIONS:

miR-23b plays key role in maintaining stemness of cervical cancer stem cells and can be developed as therapeutic target to better fight against cervical cancer.

KEYWORDS:

ALDH1A1; Cervical cancer stem cells; miR-23b

PMID:
28449663
PMCID:
PMC5408421
DOI:
10.1186/s12885-017-3192-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center